[go: up one dir, main page]

AR110405A1 - Compuestos - Google Patents

Compuestos

Info

Publication number
AR110405A1
AR110405A1 ARP170103598A ARP170103598A AR110405A1 AR 110405 A1 AR110405 A1 AR 110405A1 AR P170103598 A ARP170103598 A AR P170103598A AR P170103598 A ARP170103598 A AR P170103598A AR 110405 A1 AR110405 A1 AR 110405A1
Authority
AR
Argentina
Prior art keywords
alkyl
halogen
group
independently selected
amino
Prior art date
Application number
ARP170103598A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
C4 Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche, C4 Therapeutics Inc filed Critical Hoffmann La Roche
Publication of AR110405A1 publication Critical patent/AR110405A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/009—Sachets, pouches characterised by the material or function of the envelope
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Botany (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

Reivindicación 1: Compuesto de fórmula (1), en la que R¹ se selecciona cada uno independientemente entre el grupo que consiste en i) amino, ii) alquilo C₁₋₆, iii) alcoxi C₁₋₆, iv) ciano, v) halógeno, vi) halógenoalquilo C₁₋₆, vii) halógenoalcoxi C₁₋₆, y viii) hidroxi; R² se selecciona cada uno independientemente entre el grupo que consiste en i) amino, ii) arilo sustituido con (R³)ₖ, iii) alquilo C₁₋₆, iv) alcoxi C₁₋₆, v) alquinilo C₂₋₆ sustituido con (R⁵)ₚ, vi) ciano, vii) halógeno, viii) halógenoalquilo C₁₋₆, ix) halógenoalcoxi C₁₋₆, x) heteroarilo sustituido con (R⁴)ₗ, xi) heterociclilo sustituido con (R⁷)ʳ y xii) hidroxi; R³ se selecciona cada uno independientemente entre el grupo que consiste en i) amino, ii) alquilo C₁₋₆, iii) alcoxi C₁₋₆, iv) ciano, v) halógeno, vi) halógenoalquilo C₁₋₆, vii) halógenoalcoxi C₁₋₆, y viii) hidroxi; R⁴ se selecciona cada uno independientemente entre el grupo que consiste en i) amino, ii) alquilo C₁₋₆, iii) alcoxi C₁₋₆, iv) ciano, v) halógeno, vi) halógenoalquilo C₁₋₆, vii) halógenoalcoxi C₁₋₆, viii) heterociclilo sustituido con (R⁸)ₛ, y ix) hidroxi; R⁵ se selecciona independientemente entre el grupo que consiste en i) heteroarilo sustituido con (R⁶)q, y ii) alquilo C₁₋₆; R⁶ se selecciona independientemente entre el grupo que consiste en i) amino, y ii) alquilo C₁₋₆; R⁷ se selecciona independientemente entre el grupo que consiste en i) amino, y ii) alquilo C₁₋₆; R⁸ se selecciona independientemente entre el grupo que consiste en i) amino, y ii) alquilo C₁₋₆; Het es heteroarilo; k es 0, 1, 2 ó 3; l es 0, 1 ó 2; n es 0, 1, 2 ó 3; m es 0, 1 ó 2; p es 0, 1 ó 2; q es 0, 1 ó 2; r es 0, 1 ó 2; s es 0, 1 ó 2; o una sal farmacéuticamente aceptable del mismo.
ARP170103598A 2016-12-22 2017-12-20 Compuestos AR110405A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16206394 2016-12-22

Publications (1)

Publication Number Publication Date
AR110405A1 true AR110405A1 (es) 2019-03-27

Family

ID=57777430

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170103598A AR110405A1 (es) 2016-12-22 2017-12-20 Compuestos

Country Status (7)

Country Link
US (2) US10882848B2 (es)
EP (1) EP3558967B1 (es)
JP (1) JP7076453B2 (es)
CN (1) CN110325528B (es)
AR (1) AR110405A1 (es)
TW (1) TW201834651A (es)
WO (1) WO2018115218A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101911090B1 (ko) * 2011-12-27 2018-10-25 두산인프라코어 주식회사 인양력 증대 자세교정 장치
US10266517B2 (en) 2014-12-23 2019-04-23 Dana-Farber Cancer Institute, Inc. Pyrimidines as EGFR inhibitors and methods of treating disorders
TWI774780B (zh) * 2017-06-02 2022-08-21 瑞士商赫孚孟拉羅股份公司 化合物
JP7335275B2 (ja) 2018-02-20 2023-08-29 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｅｇｆｒの阻害剤およびその使用法
US12161649B2 (en) 2018-06-21 2024-12-10 Dana-Farber Cancer Institute, Inc. Inhibitors of EGFR and methods of use thereof
AU2019294414B2 (en) 2018-06-29 2023-06-29 F. Hoffmann-La Roche Ag Compounds
WO2020051235A1 (en) 2018-09-04 2020-03-12 C4 Therapeutics, Inc. Compounds for the degradation of brd9 or mth1
EP4470618A3 (en) 2019-03-06 2025-03-05 C4 Therapeutics, Inc. Heterocyclic compounds for medical treatment
KR20220052904A (ko) * 2019-06-21 2022-04-28 다나-파버 캔서 인스티튜트 인크. 알로스테릭 egfr 억제제 및 이의 사용 방법
LT3986897T (lt) * 2019-06-21 2023-11-10 F. Hoffmann-La Roche Ag Egfr inhibitorius, skirtas vėžiui gydyti
EP3986565B1 (en) * 2019-06-21 2023-08-30 F. Hoffmann-La Roche AG New egfr inhibitors
JOP20220107A1 (ar) 2019-11-11 2023-01-30 Dana Farber Cancer Inst Inc مثبطات egfr تفارغية وطرق استخدامها
AR120800A1 (es) * 2019-12-20 2022-03-16 Hoffmann La Roche Derivados de 6,7-dihidro-5h-pirrolo[1,2-c]imidazol como inhibidores de egfr
AR120799A1 (es) * 2019-12-20 2022-03-16 Hoffmann La Roche 2-[4-cloro-6-[2-[4-[[4-(hidroximetil)-1-piperidil]metil]fenil]etinil]-1-oxoisoindolin-2-il]-2-(6,7-dihidro-5h-pirrolo[1,2-c]imidazol-1-il)-n-tiazol-2-il-acetamida como inhibidor de egfr
CN114901277B (zh) 2019-12-20 2024-05-17 C4医药公司 用于egfr降解的异吲哚啉酮和吲唑化合物
US20230131025A1 (en) 2020-02-14 2023-04-27 Betta Pharmaceuticals Co., Ltd. Quinolyl phosphine oxide compound, and composition and application thereof
PE20240099A1 (es) * 2020-12-01 2024-01-18 Hoffmann La Roche Nuevos derivados de indazol acetileno
EP4255906A1 (en) * 2020-12-01 2023-10-11 F. Hoffmann-La Roche AG New indazole derivatives
EP4255907A1 (en) * 2020-12-01 2023-10-11 F. Hoffmann-La Roche AG New indazole derivatives
WO2023283130A1 (en) 2021-07-04 2023-01-12 Newave Pharmaceutical Inc. Isoquinoline derivatives as mutant egfr modulators and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5386350B2 (ja) * 2006-05-31 2014-01-15 タケダ カリフォルニア インコーポレイテッド グルコキナーゼ活性剤としての、インダゾールおよびイソインドール誘導体
CN102093339B (zh) * 2010-12-09 2013-06-12 天津药物研究院 一类嘧啶衍生物的制备及用途
CN102060848B (zh) * 2010-12-09 2013-09-18 天津药物研究院 芳香胺取代的嘧啶衍生物的制备及用途
CA2987914C (en) * 2015-06-30 2022-09-13 Dana-Farber Cancer Institute, Inc. Inhibitors of egfr and methods of use thereof

Also Published As

Publication number Publication date
US20210070739A1 (en) 2021-03-11
US10882848B2 (en) 2021-01-05
EP3558967A1 (en) 2019-10-30
US20190308955A1 (en) 2019-10-10
US11708354B2 (en) 2023-07-25
WO2018115218A1 (en) 2018-06-28
EP3558967B1 (en) 2022-03-02
CN110325528B (zh) 2022-10-11
TW201834651A (zh) 2018-10-01
CN110325528A (zh) 2019-10-11
JP7076453B2 (ja) 2022-05-27
JP2020502246A (ja) 2020-01-23

Similar Documents

Publication Publication Date Title
AR110405A1 (es) Compuestos
AR092349A1 (es) Imidazotriazincarbonitrilos utiles como inhibidores de quinasa
AR104884A1 (es) Compuestos de 4-hidroxi-3-(heteroaril)piridin-2-ona como agonistas de apj
AR113929A1 (es) Compuestos heterocíclicos
AR107061A1 (es) Heteroarilhidroxipirimidinonas como agonistas del receptor de apj
AR114793A1 (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de los mismos
AR100058A1 (es) DERIVADOS DE PIRIMIDIN-PIRAZINAS FUSIONADAS MODULADORES DE RORg
AR094299A1 (es) Derivados de ftalazin-1(2h)-ona sustituidos
AR097082A1 (es) Compuestos terapéuticamente activos y sus métodos de uso
PE20190326A1 (es) Isoquinolin-3-il-carboxamidas y preparacion y uso de las mismas
AR100702A1 (es) Compuestos inhibidores de quinasa de unión tank
AR102204A1 (es) Compuestos derivados de amino-alquilbenzotiazepinas
AR095311A1 (es) 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante
AR107973A1 (es) 6-hidroxi-4-oxo-1,4-dihidropirimidin-5-carboxamidas como agonista de apj
AR077695A1 (es) Derivados de pirimidina como inhibidores del factor ixa
AR099789A1 (es) Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina
AR115936A1 (es) Compuestos útiles en terapia del vih
AR112086A1 (es) Compuestos heteroaromáticos como inhibidores de vanina
AR109776A1 (es) Compuestos de p2x₃ y/o p2x₂/₃ y métodos
AR102258A1 (es) Compuestos de quinolina y quinazolina
AR109296A1 (es) Derivados de oxadiazolopiridina para el uso como inhibidores de ghrelin o-aciltransferasa (goat)
AR109711A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR101255A1 (es) Derivados de isoindolinona
AR108864A1 (es) Agentes antibacterianos
AR119376A1 (es) Compuestos heterocíclicos

Legal Events

Date Code Title Description
FB Suspension of granting procedure